Luc/GFP Reporter Cell Line-MCF7

Breast cancer has become the most commonly diagnosed malignancy worldwide and is the leading cause of cancer-related mortality in women, significantly affecting their quality of life and life expectancy. The researchers explored the role of MYSM1, a deubiquitinase, in modulating estrogen receptor alpha (ERα) activity, a key factor in endocrine resistance in ERα-positive breast cancer (BCa). They found that MYSM1 is essential for maintaining ERα stability through deubiquitination, influencing histone and non-histone proteins. MYSM1 also regulates chromatin structure, promoting gene transcription related to ERα. High MYSM1 expression was observed in clinical BCa samples, and its depletion reduced tumor growth in models and enhanced the effectiveness of antiestrogen therapies. Virtual screening suggested that Imatinib might inhibit BCa cell growth via the MYSM1-ERα pathway, offering a potential therapeutic target for overcoming endocrine resistance.

Figure 1. In MCF-7 breast cancer cells, MYSM1 binds to ERα, affecting the transcription of ERα target genes. Methods included co-immunoprecipitation, luciferase assays, GST pull-down, immunofluorescence, qPCR, and Western blot to study the interaction and functional impact of MYSM1 on ERα in MCF-7 cells. (Luan R, et al., 2024)

Creative Biogene's Luc/GFP Reporter Cell Line-MCF7 stably expresses luciferase and green fluorescent protein, allowing direct reporting of ERα-related gene activity. This cell line enables researchers to quickly assess the effects of MYSM1 on ERα target genes using simple fluorescence and luminescence assays, bypassing the need for complex construction and transfection steps. Additionally, it is effective for screening small molecule inhibitors, such as Imatinib, and evaluating their impact on the MYSM1-ERα axis. This streamlined approach accelerates research on ERα signaling, endocrine resistance, and drug discovery.